Everest Medicines (01952) Announces Monthly Equity Return for 30 November 2025

Bulletin Express12-03

Everest Medicines Limited (01952) reported that as of 30 November 2025, the authorized share capital remained at 500,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 50,000. The number of issued ordinary shares stood at 353,550,381, reflecting an increase of 2,000 shares from the previous month.

The new share issuance arose from the exercise of share options under the Post-IPO share option scheme, generating HKD 31,264 in proceeds. Under this scheme, 21,823,738 shares remain issuable, while an additional 173,573 shares may be issued through the Pre-IPO Employee Share Option Plan. Further, 3,192,123 shares remain issuable as restricted stock units under the Pre-IPO plan, and 1,860,767 shares are still issuable under the post-IPO share award scheme. During the month, 142,118 restricted stock units vested, and a total of 6,700 restricted stock units and 6,350 awards were cancelled.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166848418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166848418","market":"hk","top_or_hot":-1,"title":"Everest Medicines (01952) Announces Monthly Equity Return for 30 November 2025","media":"Bulletin Express","content":"<p>Everest Medicines Limited (01952) reported that as of 30 November 2025, the authorized share capital remained at 500,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 50,000. The number of issued ordinary shares stood at 353,550,381, reflecting an increase of 2,000 shares from the previous month.</p>\n<p>The new share issuance arose from the exercise of share options under the Post-IPO share option scheme, generating HKD 31,264 in proceeds. Under this scheme, 21,823,738 shares remain issuable, while an additional 173,573 shares may be issued through the Pre-IPO Employee Share Option Plan. Further, 3,192,123 shares remain issuable as restricted stock units under the Pre-IPO plan, and 1,860,767 shares are still issuable under the post-IPO share award scheme. During the month, 142,118 restricted stock units vested, and a total of 6,700 restricted stock units and 6,350 awards were cancelled.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest Medicines (01952) Announces Monthly Equity Return for 30 November 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest Medicines (01952) Announces Monthly Equity Return for 30 November 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-03 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Everest Medicines Limited (01952) reported that as of 30 November 2025, the authorized share capital remained at 500,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 50,000. The number of issued ordinary shares stood at 353,550,381, reflecting an increase of 2,000 shares from the previous month.</p>\n<p>The new share issuance arose from the exercise of share options under the Post-IPO share option scheme, generating HKD 31,264 in proceeds. Under this scheme, 21,823,738 shares remain issuable, while an additional 173,573 shares may be issued through the Pre-IPO Employee Share Option Plan. Further, 3,192,123 shares remain issuable as restricted stock units under the Pre-IPO plan, and 1,860,767 shares are still issuable under the post-IPO share award scheme. During the month, 142,118 restricted stock units vested, and a total of 6,700 restricted stock units and 6,350 awards were cancelled.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1166848418","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166848418","pubTimestamp":1764759928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Everest Medicines Limited (01952) reported that as of 30 November 2025, the authorized share capital remained at 500,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 50,000....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"Everest Medicines(01952)公布2025年11月30日之权益月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"Everest Medicines Limited (01952) reported that as of 30 November 2025, the authorized share capital remained at 500,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 50,000. The number of issued ordinary shares stood at 353,550,381, reflecting an increase of 2,000 shares from the previous month.\nThe new share issuance arose from the exercise of share options under the Post-IPO share option scheme, generating HKD 31,264 in proceeds. Under this scheme, 21,823,738 shares remain issuable, while an additional 173,573 shares may be issued through the Pre-IPO Employee Share Option Plan. Further, 3,192,123 shares remain issuable as restricted stock units under the Pre-IPO plan, and 1,860,767 shares are still issuable under the post-IPO share award scheme. During the month, 142,118 restricted stock units vested, and a total of 6,700 restricted stock units and 6,350 awards were cancelled.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166848418","isCrawlerRequest":true}